Targeted Antimicrobial Photodynamic Therapy of Biofilm-Embedded and Intracellular Staphylococci with a Phage Endolysin's Cell Binding Domain

• Published in: Microbiology spectrum 2022-02, Vol.10 (1), p.e0146621-e0146621
• Main Authors: Bispo, Mafalda, Santos, Sílvio B, Melo, Luís D R, Azeredo, Joana, van Dijl, Jan Maarten
• Format: Article
• Language: English
• Subjects: Animals; Anti-Bacterial Agents - chemistry; Anti-Bacterial Agents - pharmacology; Antimicrobial Chemotherapy; antimicrobial photodynamic therapy; Biofilms - drug effects; cell-binding domain; Drug Resistance, Multiple, Bacterial; endolysin; Endopeptidases - chemistry; Endopeptidases - metabolism; Endopeptidases - pharmacology; Humans; Indoles - chemistry; intracellular Staphylococcus aureus; Light; Organosilicon Compounds - chemistry; Photochemotherapy; Photosensitizing Agents - chemistry; Reactive Oxygen Species - metabolism; Research Article; Staphylococcal Infections - drug therapy; Staphylococcal Infections - microbiology; Staphylococcus - drug effects; Staphylococcus - physiology; Staphylococcus - virology; Staphylococcus aureus; Staphylococcus epidermidis; Staphylococcus Phages - chemistry; Staphylococcus Phages - metabolism
• ISSN: 2165-0497; 2165-0497
• DOI: 10.1128/spectrum.01466-21

Bacterial pathogens are progressively adapting to current antimicrobial therapies with severe consequences for patients and global health care systems. This is critically underscored by the rise of methicillin resistant Staphylococcus aureus (MRSA) and other biofilm-forming staphylococci. Accordingly, alternative strategies have been explored to fight such highly multidrug resistant microorganisms, including antimicrobial photodynamic therapy (aPDT) and phage therapy. aPDT has the great advantage that it does not elicit resistance, while phage therapy allows targeting of specific pathogens. In the present study, we aimed to merge these benefits by conjugating the cell-binding domain (CBD3) of a Staphylococcus aureus phage endolysin to a photoactivatable silicon phthalocyanine (IRDye 700DX) for the development of a Staphylococcus-targeted aPDT approach. We show that, upon red-light activation, the resulting CBD3-700DX conjugate generates reactive oxygen species that effectively kill high loads of planktonic and biofilm-resident staphylococci, including MRSA. Furthermore, CBD3-700DX is readily internalized by mammalian cells, where it allows the targeted killing of intracellular MRSA upon photoactivation. Intriguingly, aPDT with CBD3-700DX also affects mammalian cells with internalized MRSA, but it has no detectable side effects on uninfected cells. Altogether, we conclude that CBD3 represents an attractive targeting agent for Staphylococcus-specific aPDT, irrespective of planktonic, biofilm-embedded, or intracellular states of the bacterium. Antimicrobial resistance is among the biggest threats to mankind today. There are two alternative antimicrobial therapies that may help to control multidrug-resistant bacteria. In phage therapy, natural antagonists of bacteria, lytic phages, are harnessed to fight pathogens. In antimicrobial photodynamic therapy (aPDT), a photosensitizer, molecular oxygen, and light are used to produce reactive oxygen species (ROS) that inflict lethal damage on pathogens. Since aPDT destroys multiple essential components in targeted pathogens, aPDT resistance is unlikely. However, the challenge in aPDT is to maximize target specificity and minimize collateral oxidative damage to host cells. We now present an antimicrobial approach that combines the best features of both alternative therapies, namely, the high target specificity of phages and the efficacy of aPDT. This is achieved by conjugating the specific cell-binding domain from a ph